Use of Traditional Serological Methods and Oral Fluids to Assess Immunogenicity in Children Aged 2-16 years After Successive Annual Vaccinations with LAIV

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2020 Feb 20

PMID 32070679

Citations 5

Authors

Katja Hoschler

Sunil Maharjan

Heather Whitaker

Jo Southern

Blessing Okai

Janice Baldevarona

Paul J Turner

Nick J Andrews

Elizabeth Miller

Maria Zambon

Affiliations

Soon will be listed here.

Abstract

Background: The UK introduced quadrivalent live attenuated influenza vaccine (qLAIV) for children in 2013/2014. The impact of annual vaccination on effectiveness and immunogenicity is being assessed.

Method: A phase III/IV open-label study of the immunogenicity of annual vaccination with qLAIV (Fluenz™) was conducted over three consecutive years (2014/15-2016/17) in 254, 249 and 162 children respectively. Serum responses to vaccine components were measured by Haemagglutination Inhibition (HAI) and anti-A(H1N1)pdm09 Neuraminidase (NAI) assays, stratified according to previous receipt of AS03-adjuvanted A(H1N1)pdm09 pandemic vaccine in 2009/10. Antibody levels to the A(H1N1)pdm09 and H3N2 vaccine components in oral fluids (OF) were explored using an ELISA.

Findings: More paired pre- and post-vaccination oral fluids (96%) than paired sera (87%) were obtained. Geometric mean titre rises using HAI assays were limited, with maximum rises seen in year one for both influenza B strains when 39% and 43% of subjects seroconverted (95% confidence interval 33-46% and 36-50%, respectively) and year two for influenza H3N2, when 40% (33-46%) individuals seroconverted. Prior pandemic vaccine receipt resulted in higher pre- and post-vaccination A(H1N1)pdm09 HAI titres and lower pre-and post-vaccination NAI (N1 neuraminidase) titres in all three years. OF results were congruent with HAI results; assay specificity compared to HAI was 88.1 and 71.6 percent, and sensitivity was 86.4 and 74.8 percent respectively for A(H1N1)pdm09 and H3N2.

Conclusion: In all three study years, vaccination with qLAIV resulted in poor antibody responses. However, OFs are an alternative specimen type that allows self sampling, can easily be obtained from children, and their analysis leads to similar conclusions as classic serology by HAI. Their suitability for seroprevalence studies should be investigated. We demonstrated a sustained effect from prior receipt of the AS03-adjuvanted A(H1N1)pdm09 vaccine, even after repeat vaccination with qLAIV indicating that early exposure to influenza antigens has a significant long lasting effect.

Citing Articles

Exploring the pathway toward the reduction of paediatric seasonal influenza burden: school-based vaccination and surveillance.

Gori M, Fappani C, Bianchi S, Tanzi E, Zuccotti G, Amendola A J Prev Med Hyg. 2025; 65(4):E469-E472.

PMID: 40026430 PMC: 11870125. DOI: 10.15167/2421-4248/jpmh2024.65.4.3190.

Early mucosal events promote distinct mucosal and systemic antibody responses to live attenuated influenza vaccine.

Thwaites R, Uruchurtu A, Negri V, Cole M, Singh N, Poshai N Nat Commun. 2023; 14(1):8053.

PMID: 38052824 PMC: 10697962. DOI: 10.1038/s41467-023-43842-7.

Preschool-located influenza vaccination and influenza-like illness surveillance: an Italian pilot experience.

Amendola A, Borghi E, Bianchi S, Gori M, Fappani C, Barcellini L Ital J Pediatr. 2023; 49(1):91.

PMID: 37480047 PMC: 10362647. DOI: 10.1186/s13052-023-01481-0.

Saliva as a useful tool for evaluating upper mucosal antibody response to influenza.

Tsunetsugu-Yokota Y, Ito S, Adachi Y, Onodera T, Kageyama T, Takahashi Y PLoS One. 2022; 17(2):e0263419.

PMID: 35130308 PMC: 8820602. DOI: 10.1371/journal.pone.0263419.

SARS Antibody Testing in Children: Development of Oral Fluid Assays for IgG Measurements.

Hoschler K, Ijaz S, Andrews N, Ho S, Dicks S, Jegatheesan K Microbiol Spectr. 2022; 10(1):e0078621.

PMID: 34985331 PMC: 8729769. DOI: 10.1128/spectrum.00786-21.

References

Pebody R, Warburton F, Ellis J, Andrews N, Potts A, Cottrell S . End-of-season influenza vaccine effectiveness in adults and children, United Kingdom, 2016/17. Euro Surveill. 2017; 22(44). PMC: 5710133. DOI: 10.2807/1560-7917.ES.2017.22.44.17-00306. View

Hoschler K, Southern J, Thompson C, Warburton F, Andrews N, Miller E . Responses to live attenuated influenza vaccine in children vaccinated previously with Pandemrix (ASO3 adjuvanted pandemic A/H1N1pdm09). Vaccine. 2018; 36(21):3034-3040. DOI: 10.1016/j.vaccine.2018.04.017. View

Mohn K, Smith I, Sjursen H, Cox R . Immune responses after live attenuated influenza vaccination. Hum Vaccin Immunother. 2017; 14(3):571-578. PMC: 5861782. DOI: 10.1080/21645515.2017.1377376. View

Ambrose C, Wu X, Jones T, Mallory R . The role of nasal IgA in children vaccinated with live attenuated influenza vaccine. Vaccine. 2012; 30(48):6794-801. DOI: 10.1016/j.vaccine.2012.09.018. View

Pebody R, Warburton F, Ellis J, Andrews N, Potts A, Cottrell S . Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. Euro Surveill. 2016; 21(38). PMC: 5073201. DOI: 10.2807/1560-7917.ES.2016.21.38.30348. View

Vyse A, Cohen B, Ramsay M . A comparison of oral fluid collection devices for use in the surveillance of virus diseases in children. Public Health. 2001; 115(3):201-7. DOI: 10.1038/sj/ph/1900751. View

Jackson D, Pitcher M, Hudson C, Andrews N, Southern J, Ellis J . Viral Shedding in Recipients of Live Attenuated Influenza Vaccine in the 2016-2017 and 2017-2018 Influenza Seasons in the United Kingdom. Clin Infect Dis. 2019; 70(12):2505-2513. PMC: 7286380. DOI: 10.1093/cid/ciz719. View

Hoft D, Lottenbach K, Blazevic A, Turan A, Blevins T, Pacatte T . Comparisons of the Humoral and Cellular Immune Responses Induced by Live Attenuated Influenza Vaccine and Inactivated Influenza Vaccine in Adults. Clin Vaccine Immunol. 2016; 24(1). PMC: 5216430. DOI: 10.1128/CVI.00414-16. View

Rowe T, Abernathy R, Thompson W, Lu X, Lim W, Fukuda K . Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol. 1999; 37(4):937-43. PMC: 88628. DOI: 10.1128/JCM.37.4.937-943.1999. View

10.

Cobey S, Hensley S . Immune history and influenza virus susceptibility. Curr Opin Virol. 2017; 22:105-111. PMC: 5467731. DOI: 10.1016/j.coviro.2016.12.004. View

11.

Pebody R, Warburton F, Ellis J, Andrews N, Thompson C, von Wissmann B . Low effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 mid-season results. Euro Surveill. 2015; 20(5):21025. View

12.

Pebody R, McMenamin J, Nohynek H . Live attenuated influenza vaccine (LAIV): recent effectiveness results from the USA and implications for LAIV programmes elsewhere. Arch Dis Child. 2017; 103(1):101-105. DOI: 10.1136/archdischild-2016-312165. View

13.

King J, McLean H, Meece J, Levine M, Spencer S, Flannery B . Vaccine failure and serologic response to live attenuated and inactivated influenza vaccines in children during the 2013-2014 season. Vaccine. 2018; 36(9):1214-1219. DOI: 10.1016/j.vaccine.2018.01.016. View

14.

Murphy B, Phelan M, Nelson D, Yarchoan R, Tierney E, Alling D . Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses. J Clin Microbiol. 1981; 13(3):554-60. PMC: 273830. DOI: 10.1128/jcm.13.3.554-560.1981. View

15.

McKie A, Vyse A, Maple C . Novel methods for the detection of microbial antibodies in oral fluid. Lancet Infect Dis. 2002; 2(1):18-24. DOI: 10.1016/s1473-3099(01)00169-4. View

16.

de Azevedo Neto R, Richards A, Nokes D, Silveira A, Cohen B, Passos S . Salivary antibody detection in epidemiological surveys: a pilot study after a mass vaccination campaign against rubella in São Paulo, Brazil. Trans R Soc Trop Med Hyg. 1995; 89(1):115-8. DOI: 10.1016/0035-9203(95)90680-0. View

17.

Trombetta C, Remarque E, Mortier D, Montomoli E . Comparison of hemagglutination inhibition, single radial hemolysis, virus neutralization assays, and ELISA to detect antibody levels against seasonal influenza viruses. Influenza Other Respir Viruses. 2018; 12(6):675-686. PMC: 6185893. DOI: 10.1111/irv.12591. View

18.

Lewis K, Ortiz J, Rahman M, Levine M, Rudenko L, Wright P . Immunogenicity and Viral Shedding of Russian-Backbone, Seasonal, Trivalent, Live, Attenuated Influenza Vaccine in a Phase II, Randomized, Placebo-Controlled Trial Among Preschool-Aged Children in Urban Bangladesh. Clin Infect Dis. 2018; 69(5):777-785. PMC: 6695509. DOI: 10.1093/cid/ciy1003. View

19.

Hoschler K, Andrews N, Faust S, Finn A, Pollard A, Snape M . Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later. Clin Infect Dis. 2013; 58(2):181-7. DOI: 10.1093/cid/cit692. View

20.

Nunez I, Carlock M, Allen J, Owino S, Moehling K, Nowalk P . Impact of age and pre-existing influenza immune responses in humans receiving split inactivated influenza vaccine on the induction of the breadth of antibodies to influenza A strains. PLoS One. 2017; 12(11):e0185666. PMC: 5665503. DOI: 10.1371/journal.pone.0185666. View